Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer

Kyverna Therapeutics appointed Nadia Dac as Chief Commercial Officer, effective May 4, to lead commercial strategy for its lead asset miv-cel in preparation for a potential first approval in stiff person syndrome. Ms. Dac brings over 30 years of experience, having previously led commercial launches at Omeros Corporation and Alder Biopharmaceuticals, and will focus on building Kyverna's neuroimmunology franchise. In connection with the appointment, Kyverna granted Ms.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.